Adjuvant

Adjuvant Therapy Market Overview 2022 to 2030, Future Trends and Forecast | By -Merck, Bayer, Johnson & Johnson

The Global Adjuvant Therapy Market investigation report contains Types ( Chemotherapy, Radiotherapy, Hormonotherapy, Others ), Segmentation & all logical and factual briefs about the Market 2022 ... read more

Aluminum-based Vaccine Adjuvant Market : Research Report Provides an In-Depth Insight of Trends 2022 To 2028

Aluminum-based Vaccine Adjuvant Market Research Report is spread across 85 Pages and provides exclusive data, information, vital statistics, trends, and competitive landscape details in this niche ... read more

Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients

1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in PD-L1 unselected non-small-cell lung cancer patients who underwent complete resection. 2. Adverse ... read more

Adjuvant nivolumab + ipilimumab lacks efficacy for localized renal cell carcinoma

Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for ... read more

Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma

During a press briefing, Motzer was asked to put his findings into context considering the results of the KEYNOTE-564 trial, which led to FDA approval of pembrolizumab for adjuvant treatment of ... read more

Adjuvant Nivolumab-Ipilimumab Failed to Improve DFS in Renal Cell Carcinoma

Source: Getty Images Adjuvant nivolumab plus ipilimumab is no more effective than placebo after resection of localized, high-risk renal cell carcinoma (RCC), according to phase 3 results presented ... read more

Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma

"Compared to the same treatment given entirely in the adjuvant setting, neoadjuvant pembrolizumab, followed by adjuvant pembrolizumab, improves event-free survival in resectable melanoma," she said. read more

AstraZeneca: Tagrisso demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer

Updated results from the pivotal ADAURA Phase III trial showed that AstraZeneca's Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful improvement in disease-free survival (DFS) ... read more

Dr Igor Puzanov Discusses the State of Adjuvant Therapy for Advanced Melanoma

The interview has been edited for clarity. AJMC ®: What factors do you evaluate when considering the initiation of adjuvant therapy for a patient with resected advanced disease? We do consider ... read more

Opdivo set to take on Keytruda in adjuvant melanoma

Bristol-Myers Squibb’s Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient death in ... read more